[Asia Economy Reporter Ji Yeon-jin] HL Biopharma announced on the 21st that it has decided to issue convertible bonds with warrants worth 57 billion KRW.
The bond maturity date is October 20, 2026, and the conversion into new shares can be exercised from October 22 next year. The exercise price is 51,262 KRW per share.
The company stated that the entire proceeds from the bond issuance will be used as the acquisition cost for the unlisted corporation FA.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
